Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Harvoni for Porphyria Cutanea Tarda in Chronic Hepatitis C
NCT03118674Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Sep 2017
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ledipasvir in porphyria cutanea tarda (PCT), sponsored by Wake Forest University Health Sciences. Primary endpoint: Number of Participants With Resolution of Active PCT at 7 months. Started Sep 2017; status: completed.
02
Drugs
ledipasvir
03
Conditions
porphyria cutanea tarda (PCT)
Beyond the preview
Go deeper on NCT03118674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03118674.